Neurofibroma and schwannoma
- PMID: 12447105
- DOI: 10.1097/01.wco.0000044763.39452.aa
Neurofibroma and schwannoma
Abstract
Purpose of review: Neurofibromas and schwannomas are benign peripheral nerve sheath tumours that occur as isolated sporadic lesions, but have their major clinical impact on the neurocutaneous diseases neurofibromatosis 1 and neurofibromatosis 2. The gene products neurofibromin and merlin (schwannomin), respectively, are thought to act as tumour suppressors. The aim of this review is to document recent advances in our understanding of the clinical characteristics and pathogenesis of neurofibromas and schwannomas in the neurofibromatoses.
Recent findings: Animal models have shed light on the pathogenesis of neurofibromas confirming that the Schwann cell initiates neurofibroma formation. New data suggest that individuals with neurofibromatosis 1 have a 10% lifetime risk of developing malignant peripheral nerve sheath tumours. Positron emission tomography with the glucose analogue 18-fluorodeoxyglucose might be helpful in the diagnosis of malignant peripheral nerve sheath tumours. Such tumours associated with neurofibromatosis 1 show a loss of neurofibromatosis 1 expression and high levels of Ras, but malignant transformation requires additional genetic events that inactivate key cell cycle regulators. Neurofibromatosis 2-associated vestibular schwannomas have variable growth rates that tend to decline with age. Early microsurgery for small tumours results in optimal preservation of hearing and facial nerve function. Currently, radiosurgery for these lesions produces similar results. Systematic follow-up of both groups will determine the best treatment method. Merlin's function as a tumour suppressor has not been elucidated. The control of cell cycle progression and abnormal intracellular and extracellular signalling could all play a part.
Summary: Molecular advances will allow a biological approach to targeted therapies for neurofibromas, malignant peripheral nerve sheath tumours and schwannomas. Knowledge of the pathogenesis of these tumours will have implications for our understanding of the neurofibromatoses and of the formation of sporadic tumours.
Copyright 2002 Lippincott Williams & Wilkins
Similar articles
-
An algorithmic approach to the management of peripheral nerve tumours.J Hand Surg Eur Vol. 2024 Jun;49(6):758-772. doi: 10.1177/17531934241238739. Epub 2024 Mar 27. J Hand Surg Eur Vol. 2024. PMID: 38534080 Review.
-
Advances in the treatment of neurofibromatosis-associated tumours.Nat Rev Clin Oncol. 2013 Nov;10(11):616-24. doi: 10.1038/nrclinonc.2013.144. Epub 2013 Aug 13. Nat Rev Clin Oncol. 2013. PMID: 23939548 Review.
-
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7. doi: 10.1136/jnnp.68.3.353. J Neurol Neurosurg Psychiatry. 2000. PMID: 10675220 Free PMC article.
-
[Pathologic characteristics of the most frequent peripheral nerve tumors].Neurochirurgie. 2009 Oct;55(4-5):454-8. doi: 10.1016/j.neuchi.2009.07.001. Epub 2009 Sep 9. Neurochirurgie. 2009. PMID: 19744677 Review. French.
-
SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog.Hum Pathol. 2011 Mar;42(3):434-43. doi: 10.1016/j.humpath.2010.02.020. Epub 2010 Dec 28. Hum Pathol. 2011. PMID: 21193222
Cited by
-
PET Scanning May Not Distinguish Benign Schwannoma from Metastasis in a Patient with Lung Adenocarcinoma.Eur J Case Rep Intern Med. 2023 Aug 31;10(10):004048. doi: 10.12890/2023_004048. eCollection 2023. Eur J Case Rep Intern Med. 2023. PMID: 37789974 Free PMC article.
-
Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions.Curr Oncol. 2023 Apr 24;30(5):4437-4482. doi: 10.3390/curroncol30050338. Curr Oncol. 2023. PMID: 37232796 Free PMC article. Review.
-
Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve.J Korean Med Sci. 2009 Aug;24(4):763-6. doi: 10.3346/jkms.2009.24.4.763. Epub 2009 Jul 30. J Korean Med Sci. 2009. PMID: 19654968 Free PMC article.
-
L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review.Nutrients. 2024 Apr 20;16(8):1232. doi: 10.3390/nu16081232. Nutrients. 2024. PMID: 38674921 Free PMC article.
-
Tumors of the peripheral nerves and plexuses.Curr Treat Options Neurol. 2006 Jul;8(4):299-308. doi: 10.1007/s11940-006-0020-z. Curr Treat Options Neurol. 2006. PMID: 16942673
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials